new BindingDB logo
myBDB logout
Compile Data Set for Download or QSAR

Found 502 hits with Last Name = 'bisacchi' and Initial = 'gs'   
Target/Host
(Institution)
LigandTarget/Host
Links
Ligand
Links
Trg + Lig
Links
Ki
nM
ΔG°
kJ/mole
IC50
nM
Kd
nM
EC50/IC50
nM
koff
s-1
kon
M-1s-1
pHTemp
°C
Coagulation factor XI


(Homo sapiens (Human))
BDBM50448583
PNG
(CHEMBL3127491)
Show SMILES CC(C)CC(=O)Nc1cc(cc(c1)-c1ccc(cc1C(O)=O)C(N)=O)[C@@H]1C[C@](C)(c2ccccc2)c2cc(ccc2N1)C(N)=N |r|
Show InChI InChI=1S/C36H37N5O4/c1-20(2)13-32(42)40-26-15-23(27-11-9-22(34(39)43)17-28(27)35(44)45)14-24(16-26)31-19-36(3,25-7-5-4-6-8-25)29-18-21(33(37)38)10-12-30(29)41-31/h4-12,14-18,20,31,41H,13,19H2,1-3H3,(H3,37,38)(H2,39,43)(H,40,42)(H,44,45)/t31-,36+/m0/s1
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
PDB
UniChem
PDB
Article
PubMed
0.200n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human coagulation factor 11a using p-nitroaniline as substrate assessed as substrate hydrolysis by spectrophotometrically


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
3D
3D Structure (crystal)
Coagulation factor XI


(Homo sapiens (Human))
BDBM50032873
PNG
(CHEMBL3355684)
Show SMILES OC(=O)C(F)(F)F.NC[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](Cc1ccccc1)c1nc(c(F)[nH]1)-c1ccc2c(N)n[nH]c2c1 |r,wU:12.14,wD:9.7,18.17,(38,-31.47,;39.32,-32.23,;39.32,-33.76,;40.64,-31.46,;41.96,-32.23,;40.64,-29.94,;41.95,-30.68,;15.71,-45.09,;16.47,-43.75,;18.01,-43.75,;18.79,-45.09,;20.33,-45.09,;21.09,-43.75,;20.33,-42.42,;18.79,-42.42,;22.63,-43.75,;23.41,-45.09,;23.41,-42.42,;24.95,-42.42,;25.71,-43.75,;27.25,-43.75,;28.03,-42.42,;29.57,-42.42,;30.33,-43.75,;29.57,-45.09,;28.03,-45.09,;25.71,-41.09,;25.09,-39.68,;26.23,-38.65,;27.56,-39.42,;28.97,-38.79,;27.24,-40.93,;26.07,-37.12,;27.32,-36.22,;27.16,-34.69,;25.75,-34.05,;25.27,-32.59,;26.18,-31.34,;23.73,-32.59,;23.25,-34.05,;24.5,-34.96,;24.66,-36.49,)|
Show InChI InChI=1/C26H30FN7O.C2HF3O2/c27-23-22(18-10-11-19-20(13-18)33-34-24(19)29)31-25(32-23)21(12-15-4-2-1-3-5-15)30-26(35)17-8-6-16(14-28)7-9-17;3-2(4,5)1(6)7/h1-5,10-11,13,16-17,21H,6-9,12,14,28H2,(H,30,35)(H,31,32)(H3,29,33,34);(H,6,7)/t16-,17-,21-;/s2
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Patents

Article
PubMed
0.300n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human coagulation factor 11a using p-nitroaniline as substrate assessed as substrate hydrolysis by spectrophotometrically


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Coagulation factor XI


(Homo sapiens (Human))
BDBM50032874
PNG
(CHEMBL3355683)
Show SMILES OC(=O)C(F)(F)F.NC[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](Cc1ccccc1)c1nc(c(Cl)[nH]1)-c1ccc2c(N)n[nH]c2c1 |r,wU:12.14,wD:9.7,18.17,(34.53,-30.97,;35.85,-31.73,;35.85,-33.26,;37.17,-30.97,;38.49,-31.73,;37.17,-29.44,;38.49,-30.19,;15.69,-45.08,;16.46,-43.74,;18,-43.74,;18.77,-45.08,;20.31,-45.08,;21.08,-43.74,;20.31,-42.42,;18.77,-42.42,;22.62,-43.74,;23.39,-45.08,;23.39,-42.42,;24.93,-42.42,;25.7,-43.74,;27.24,-43.74,;28.01,-42.42,;29.55,-42.42,;30.32,-43.74,;29.55,-45.08,;28.01,-45.08,;25.7,-41.08,;25.07,-39.67,;26.21,-38.64,;27.55,-39.42,;28.96,-38.78,;27.23,-40.92,;26.05,-37.11,;27.3,-36.21,;27.14,-34.68,;25.73,-34.05,;25.26,-32.58,;26.16,-31.33,;23.72,-32.58,;23.24,-34.05,;24.49,-34.96,;24.65,-36.49,)|
Show InChI InChI=1/C26H30ClN7O.C2HF3O2/c27-23-22(18-10-11-19-20(13-18)33-34-24(19)29)31-25(32-23)21(12-15-4-2-1-3-5-15)30-26(35)17-8-6-16(14-28)7-9-17;3-2(4,5)1(6)7/h1-5,10-11,13,16-17,21H,6-9,12,14,28H2,(H,30,35)(H,31,32)(H3,29,33,34);(H,6,7)/t16-,17-,21-;/s2
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.300n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human coagulation factor 11a using p-nitroaniline as substrate assessed as substrate hydrolysis by spectrophotometrically


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Coagulation factor XI


(Homo sapiens (Human))
BDBM50032874
PNG
(CHEMBL3355683)
Show SMILES OC(=O)C(F)(F)F.NC[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](Cc1ccccc1)c1nc(c(Cl)[nH]1)-c1ccc2c(N)n[nH]c2c1 |r,wU:12.14,wD:9.7,18.17,(34.53,-30.97,;35.85,-31.73,;35.85,-33.26,;37.17,-30.97,;38.49,-31.73,;37.17,-29.44,;38.49,-30.19,;15.69,-45.08,;16.46,-43.74,;18,-43.74,;18.77,-45.08,;20.31,-45.08,;21.08,-43.74,;20.31,-42.42,;18.77,-42.42,;22.62,-43.74,;23.39,-45.08,;23.39,-42.42,;24.93,-42.42,;25.7,-43.74,;27.24,-43.74,;28.01,-42.42,;29.55,-42.42,;30.32,-43.74,;29.55,-45.08,;28.01,-45.08,;25.7,-41.08,;25.07,-39.67,;26.21,-38.64,;27.55,-39.42,;28.96,-38.78,;27.23,-40.92,;26.05,-37.11,;27.3,-36.21,;27.14,-34.68,;25.73,-34.05,;25.26,-32.58,;26.16,-31.33,;23.72,-32.58,;23.24,-34.05,;24.49,-34.96,;24.65,-36.49,)|
Show InChI InChI=1/C26H30ClN7O.C2HF3O2/c27-23-22(18-10-11-19-20(13-18)33-34-24(19)29)31-25(32-23)21(12-15-4-2-1-3-5-15)30-26(35)17-8-6-16(14-28)7-9-17;3-2(4,5)1(6)7/h1-5,10-11,13,16-17,21H,6-9,12,14,28H2,(H,30,35)(H,31,32)(H3,29,33,34);(H,6,7)/t16-,17-,21-;/s2
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.800n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human coagulation factor 11a using p-nitroaniline as substrate assessed as substrate hydrolysis at 37 degC by spectrophotometrically


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM50448583
PNG
(CHEMBL3127491)
Show SMILES CC(C)CC(=O)Nc1cc(cc(c1)-c1ccc(cc1C(O)=O)C(N)=O)[C@@H]1C[C@](C)(c2ccccc2)c2cc(ccc2N1)C(N)=N |r|
Show InChI InChI=1S/C36H37N5O4/c1-20(2)13-32(42)40-26-15-23(27-11-9-22(34(39)43)17-28(27)35(44)45)14-24(16-26)31-19-36(3,25-7-5-4-6-8-25)29-18-21(33(37)38)10-12-30(29)41-31/h4-12,14-18,20,31,41H,13,19H2,1-3H3,(H3,37,38)(H2,39,43)(H,40,42)(H,44,45)/t31-,36+/m0/s1
PDB

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
PDB
UniChem
Article
PubMed
2n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-pNA as substrate


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM50032873
PNG
(CHEMBL3355684)
Show SMILES OC(=O)C(F)(F)F.NC[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](Cc1ccccc1)c1nc(c(F)[nH]1)-c1ccc2c(N)n[nH]c2c1 |r,wU:12.14,wD:9.7,18.17,(38,-31.47,;39.32,-32.23,;39.32,-33.76,;40.64,-31.46,;41.96,-32.23,;40.64,-29.94,;41.95,-30.68,;15.71,-45.09,;16.47,-43.75,;18.01,-43.75,;18.79,-45.09,;20.33,-45.09,;21.09,-43.75,;20.33,-42.42,;18.79,-42.42,;22.63,-43.75,;23.41,-45.09,;23.41,-42.42,;24.95,-42.42,;25.71,-43.75,;27.25,-43.75,;28.03,-42.42,;29.57,-42.42,;30.33,-43.75,;29.57,-45.09,;28.03,-45.09,;25.71,-41.09,;25.09,-39.68,;26.23,-38.65,;27.56,-39.42,;28.97,-38.79,;27.24,-40.93,;26.07,-37.12,;27.32,-36.22,;27.16,-34.69,;25.75,-34.05,;25.27,-32.59,;26.18,-31.34,;23.73,-32.59,;23.25,-34.05,;24.5,-34.96,;24.66,-36.49,)|
Show InChI InChI=1/C26H30FN7O.C2HF3O2/c27-23-22(18-10-11-19-20(13-18)33-34-24(19)29)31-25(32-23)21(12-15-4-2-1-3-5-15)30-26(35)17-8-6-16(14-28)7-9-17;3-2(4,5)1(6)7/h1-5,10-11,13,16-17,21H,6-9,12,14,28H2,(H,30,35)(H,31,32)(H3,29,33,34);(H,6,7)/t16-,17-,21-;/s2
PDB

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Patents

Article
PubMed
2n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-pNA as substrate


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Coagulation factor XI


(Homo sapiens (Human))
BDBM50032876
PNG
(CHEMBL3355681)
Show SMILES OC(=O)C(F)(F)F.NC[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](Cc1ccccc1)c1nc(c(F)[nH]1)-c1ccc(cc1)C(N)=O |r,wU:18.18,12.14,wD:9.7,(29.83,-22.98,;31.17,-23.75,;31.17,-25.29,;32.5,-22.98,;33.84,-23.75,;33.83,-22.19,;32.5,-21.43,;13.75,-29.96,;15.08,-30.74,;16.42,-29.97,;17.76,-30.75,;19.1,-29.98,;19.09,-28.44,;17.76,-27.67,;16.42,-28.43,;20.42,-27.67,;20.42,-26.13,;21.76,-28.44,;23.09,-27.67,;23.09,-26.13,;24.43,-25.36,;25.76,-26.13,;27.09,-25.36,;27.1,-23.82,;25.75,-23.05,;24.42,-23.82,;24.43,-28.44,;25.83,-27.81,;26.86,-28.95,;26.09,-30.29,;26.72,-31.7,;24.58,-29.97,;28.39,-28.8,;29.01,-27.39,;30.53,-27.23,;31.45,-28.47,;30.82,-29.88,;29.29,-30.04,;32.98,-28.31,;33.89,-29.55,;33.61,-26.9,)|
Show InChI InChI=1/C26H30FN5O2.C2HF3O2/c27-23-22(18-10-12-19(13-11-18)24(29)33)31-25(32-23)21(14-16-4-2-1-3-5-16)30-26(34)20-8-6-17(15-28)7-9-20;3-2(4,5)1(6)7/h1-5,10-13,17,20-21H,6-9,14-15,28H2,(H2,29,33)(H,30,34)(H,31,32);(H,6,7)/t17-,20-,21-;/s2
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
3n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human coagulation factor 11a using p-nitroaniline as substrate assessed as substrate hydrolysis by spectrophotometrically


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Coagulation factor XI


(Homo sapiens (Human))
BDBM50032875
PNG
(CHEMBL3355682)
Show SMILES OC(=O)C(F)(F)F.NC[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](Cc1ccccc1)c1nc(c[nH]1)-c1ccc2c(N)n[nH]c2c1 |r,wU:12.14,wD:9.7,18.17,(39.15,-34.6,;40.47,-35.36,;40.47,-36.89,;41.79,-34.6,;43.11,-35.36,;41.79,-33.07,;43.11,-33.82,;26.66,-34.02,;27.43,-35.36,;26.66,-36.68,;25.12,-36.68,;24.35,-38.02,;25.12,-39.35,;26.66,-39.35,;27.43,-38.02,;24.35,-40.69,;22.81,-40.69,;25.12,-42.02,;24.35,-43.36,;22.81,-43.36,;22.04,-44.69,;22.81,-46.02,;22.04,-47.35,;20.5,-47.35,;19.73,-46.02,;20.5,-44.69,;25.12,-44.69,;26.65,-44.85,;26.97,-46.36,;25.64,-47.13,;24.49,-46.1,;28.38,-46.98,;28.54,-48.51,;29.95,-49.15,;31.19,-48.24,;32.7,-48.56,;33.32,-49.96,;33.47,-47.22,;32.44,-46.08,;31.03,-46.71,;29.63,-46.08,)|
Show InChI InChI=1/C26H31N7O.C2HF3O2/c27-14-17-6-8-18(9-7-17)26(34)31-22(12-16-4-2-1-3-5-16)25-29-15-23(30-25)19-10-11-20-21(13-19)32-33-24(20)28;3-2(4,5)1(6)7/h1-5,10-11,13,15,17-18,22H,6-9,12,14,27H2,(H,29,30)(H,31,34)(H3,28,32,33);(H,6,7)/t17-,18-,22-;/s2
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
3n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human coagulation factor 11a using p-nitroaniline as substrate assessed as substrate hydrolysis by spectrophotometrically


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Coagulation factor XI


(Homo sapiens (Human))
BDBM50032877
PNG
(CHEMBL3355680)
Show SMILES OC(=O)C(F)(F)F.NC[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](Cc1ccccc1)c1nc(c(Cl)[nH]1)-c1ccc(cc1)C(N)=O |r,wU:18.18,12.14,wD:9.7,(29.83,-22.98,;31.17,-23.75,;31.17,-25.29,;32.5,-22.98,;33.84,-23.75,;33.83,-22.19,;32.5,-21.43,;13.75,-29.96,;15.08,-30.74,;16.42,-29.97,;17.76,-30.75,;19.1,-29.98,;19.09,-28.44,;17.76,-27.67,;16.42,-28.43,;20.42,-27.67,;20.42,-26.13,;21.76,-28.44,;23.09,-27.67,;23.09,-26.13,;24.43,-25.36,;25.76,-26.13,;27.09,-25.36,;27.1,-23.82,;25.75,-23.05,;24.42,-23.82,;24.43,-28.44,;25.83,-27.81,;26.86,-28.95,;26.09,-30.29,;26.72,-31.7,;24.58,-29.97,;28.39,-28.8,;29.01,-27.39,;30.53,-27.23,;31.45,-28.47,;30.82,-29.88,;29.29,-30.04,;32.98,-28.31,;33.89,-29.55,;33.61,-26.9,)|
Show InChI InChI=1/C26H30ClN5O2.C2HF3O2/c27-23-22(18-10-12-19(13-11-18)24(29)33)31-25(32-23)21(14-16-4-2-1-3-5-16)30-26(34)20-8-6-17(15-28)7-9-20;3-2(4,5)1(6)7/h1-5,10-13,17,20-21H,6-9,14-15,28H2,(H2,29,33)(H,30,34)(H,31,32);(H,6,7)/t17-,20-,21-;/s2
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
4n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human coagulation factor 11a using p-nitroaniline as substrate assessed as substrate hydrolysis by spectrophotometrically


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM50032874
PNG
(CHEMBL3355683)
Show SMILES OC(=O)C(F)(F)F.NC[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](Cc1ccccc1)c1nc(c(Cl)[nH]1)-c1ccc2c(N)n[nH]c2c1 |r,wU:12.14,wD:9.7,18.17,(34.53,-30.97,;35.85,-31.73,;35.85,-33.26,;37.17,-30.97,;38.49,-31.73,;37.17,-29.44,;38.49,-30.19,;15.69,-45.08,;16.46,-43.74,;18,-43.74,;18.77,-45.08,;20.31,-45.08,;21.08,-43.74,;20.31,-42.42,;18.77,-42.42,;22.62,-43.74,;23.39,-45.08,;23.39,-42.42,;24.93,-42.42,;25.7,-43.74,;27.24,-43.74,;28.01,-42.42,;29.55,-42.42,;30.32,-43.74,;29.55,-45.08,;28.01,-45.08,;25.7,-41.08,;25.07,-39.67,;26.21,-38.64,;27.55,-39.42,;28.96,-38.78,;27.23,-40.92,;26.05,-37.11,;27.3,-36.21,;27.14,-34.68,;25.73,-34.05,;25.26,-32.58,;26.16,-31.33,;23.72,-32.58,;23.24,-34.05,;24.49,-34.96,;24.65,-36.49,)|
Show InChI InChI=1/C26H30ClN7O.C2HF3O2/c27-23-22(18-10-11-19-20(13-18)33-34-24(19)29)31-25(32-23)21(12-15-4-2-1-3-5-15)30-26(35)17-8-6-16(14-28)7-9-17;3-2(4,5)1(6)7/h1-5,10-11,13,16-17,21H,6-9,12,14,28H2,(H,30,35)(H,31,32)(H3,29,33,34);(H,6,7)/t16-,17-,21-;/s2
PDB

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
5n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-pNA as substrate


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM50032876
PNG
(CHEMBL3355681)
Show SMILES OC(=O)C(F)(F)F.NC[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](Cc1ccccc1)c1nc(c(F)[nH]1)-c1ccc(cc1)C(N)=O |r,wU:18.18,12.14,wD:9.7,(29.83,-22.98,;31.17,-23.75,;31.17,-25.29,;32.5,-22.98,;33.84,-23.75,;33.83,-22.19,;32.5,-21.43,;13.75,-29.96,;15.08,-30.74,;16.42,-29.97,;17.76,-30.75,;19.1,-29.98,;19.09,-28.44,;17.76,-27.67,;16.42,-28.43,;20.42,-27.67,;20.42,-26.13,;21.76,-28.44,;23.09,-27.67,;23.09,-26.13,;24.43,-25.36,;25.76,-26.13,;27.09,-25.36,;27.1,-23.82,;25.75,-23.05,;24.42,-23.82,;24.43,-28.44,;25.83,-27.81,;26.86,-28.95,;26.09,-30.29,;26.72,-31.7,;24.58,-29.97,;28.39,-28.8,;29.01,-27.39,;30.53,-27.23,;31.45,-28.47,;30.82,-29.88,;29.29,-30.04,;32.98,-28.31,;33.89,-29.55,;33.61,-26.9,)|
Show InChI InChI=1/C26H30FN5O2.C2HF3O2/c27-23-22(18-10-12-19(13-11-18)24(29)33)31-25(32-23)21(14-16-4-2-1-3-5-16)30-26(34)20-8-6-17(15-28)7-9-20;3-2(4,5)1(6)7/h1-5,10-13,17,20-21H,6-9,14-15,28H2,(H2,29,33)(H,30,34)(H,31,32);(H,6,7)/t17-,20-,21-;/s2
PDB

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
8n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-pNA as substrate


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Coagulation factor XI


(Homo sapiens (Human))
BDBM50032878
PNG
(CHEMBL3355679)
Show SMILES OC(=O)C(F)(F)F.NC[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](Cc1ccccc1)c1nc(c(Br)[nH]1)-c1ccc(cc1)C(N)=O |r,wU:18.18,12.14,wD:9.7,(29.77,-17.68,;31.11,-18.45,;31.11,-19.99,;32.44,-17.68,;33.78,-18.45,;33.77,-16.89,;32.44,-16.14,;13.69,-24.66,;15.02,-25.44,;16.36,-24.67,;17.7,-25.45,;19.04,-24.68,;19.03,-23.14,;17.7,-22.37,;16.36,-23.13,;20.36,-22.37,;20.36,-20.83,;21.69,-23.14,;23.03,-22.37,;23.03,-20.83,;24.37,-20.06,;25.7,-20.83,;27.03,-20.07,;27.03,-18.52,;25.69,-17.75,;24.36,-18.53,;24.36,-23.14,;25.77,-22.51,;26.8,-23.65,;26.03,-24.99,;26.66,-26.41,;24.52,-24.67,;28.32,-23.5,;28.94,-22.09,;30.47,-21.93,;31.39,-23.18,;30.76,-24.58,;29.23,-24.74,;32.92,-23.01,;33.83,-24.25,;33.55,-21.6,)|
Show InChI InChI=1/C26H30BrN5O2.C2HF3O2/c27-23-22(18-10-12-19(13-11-18)24(29)33)31-25(32-23)21(14-16-4-2-1-3-5-16)30-26(34)20-8-6-17(15-28)7-9-20;3-2(4,5)1(6)7/h1-5,10-13,17,20-21H,6-9,14-15,28H2,(H2,29,33)(H,30,34)(H,31,32);(H,6,7)/t17-,20-,21-;/s2
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
9n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human coagulation factor 11a using p-nitroaniline as substrate assessed as substrate hydrolysis by spectrophotometrically


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Coagulation factor X


(Homo sapiens (Human))
BDBM50175075
PNG
((S,Z)-4-hydroxybutyl 2-cyano-3-(2-methylbenzofuran...)
Show SMILES Cc1cc2cc(ccc2o1)N=C(N[C@H]1CCCCN(CC(=O)N2CCCC2)C1=O)C(C#N)C(=O)OCCCCO |w:10.11|
Show InChI InChI=1S/C29H37N5O6/c1-20-16-21-17-22(9-10-25(21)40-20)31-27(23(18-30)29(38)39-15-7-6-14-35)32-24-8-2-3-13-34(28(24)37)19-26(36)33-11-4-5-12-33/h9-10,16-17,23-24,35H,2-8,11-15,19H2,1H3,(H,31,32)/t23?,24-/m0/s1
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
12n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL


Assay Description
Inhibitory activity against human FXa


Bioorg Med Chem Lett 15: 5453-8 (2005)


Article DOI: 10.1016/j.bmcl.2005.08.107
BindingDB Entry DOI: 10.7270/Q2KH0MW5
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM50032877
PNG
(CHEMBL3355680)
Show SMILES OC(=O)C(F)(F)F.NC[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](Cc1ccccc1)c1nc(c(Cl)[nH]1)-c1ccc(cc1)C(N)=O |r,wU:18.18,12.14,wD:9.7,(29.83,-22.98,;31.17,-23.75,;31.17,-25.29,;32.5,-22.98,;33.84,-23.75,;33.83,-22.19,;32.5,-21.43,;13.75,-29.96,;15.08,-30.74,;16.42,-29.97,;17.76,-30.75,;19.1,-29.98,;19.09,-28.44,;17.76,-27.67,;16.42,-28.43,;20.42,-27.67,;20.42,-26.13,;21.76,-28.44,;23.09,-27.67,;23.09,-26.13,;24.43,-25.36,;25.76,-26.13,;27.09,-25.36,;27.1,-23.82,;25.75,-23.05,;24.42,-23.82,;24.43,-28.44,;25.83,-27.81,;26.86,-28.95,;26.09,-30.29,;26.72,-31.7,;24.58,-29.97,;28.39,-28.8,;29.01,-27.39,;30.53,-27.23,;31.45,-28.47,;30.82,-29.88,;29.29,-30.04,;32.98,-28.31,;33.89,-29.55,;33.61,-26.9,)|
Show InChI InChI=1/C26H30ClN5O2.C2HF3O2/c27-23-22(18-10-12-19(13-11-18)24(29)33)31-25(32-23)21(14-16-4-2-1-3-5-16)30-26(34)20-8-6-17(15-28)7-9-20;3-2(4,5)1(6)7/h1-5,10-13,17,20-21H,6-9,14-15,28H2,(H2,29,33)(H,30,34)(H,31,32);(H,6,7)/t17-,20-,21-;/s2
PDB

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
20n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-pNA as substrate


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Trypsin


(Homo sapiens (Human))
BDBM50032874
PNG
(CHEMBL3355683)
Show SMILES OC(=O)C(F)(F)F.NC[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](Cc1ccccc1)c1nc(c(Cl)[nH]1)-c1ccc2c(N)n[nH]c2c1 |r,wU:12.14,wD:9.7,18.17,(34.53,-30.97,;35.85,-31.73,;35.85,-33.26,;37.17,-30.97,;38.49,-31.73,;37.17,-29.44,;38.49,-30.19,;15.69,-45.08,;16.46,-43.74,;18,-43.74,;18.77,-45.08,;20.31,-45.08,;21.08,-43.74,;20.31,-42.42,;18.77,-42.42,;22.62,-43.74,;23.39,-45.08,;23.39,-42.42,;24.93,-42.42,;25.7,-43.74,;27.24,-43.74,;28.01,-42.42,;29.55,-42.42,;30.32,-43.74,;29.55,-45.08,;28.01,-45.08,;25.7,-41.08,;25.07,-39.67,;26.21,-38.64,;27.55,-39.42,;28.96,-38.78,;27.23,-40.92,;26.05,-37.11,;27.3,-36.21,;27.14,-34.68,;25.73,-34.05,;25.26,-32.58,;26.16,-31.33,;23.72,-32.58,;23.24,-34.05,;24.49,-34.96,;24.65,-36.49,)|
Show InChI InChI=1/C26H30ClN7O.C2HF3O2/c27-23-22(18-10-11-19-20(13-18)33-34-24(19)29)31-25(32-23)21(12-15-4-2-1-3-5-15)30-26(35)17-8-6-16(14-28)7-9-17;3-2(4,5)1(6)7/h1-5,10-11,13,16-17,21H,6-9,12,14,28H2,(H,30,35)(H,31,32)(H3,29,33,34);(H,6,7)/t16-,17-,21-;/s2
PDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
23n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human coagulation trypsin using N-benzoyl-Ile-Glu-(OH, OMe)-Gly-Arg-pNA as substrate by spectrophotometric analysis


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Human immunodeficiency virus type 1 protease


(Human immunodeficiency virus type 1)
BDBM50284925
PNG
(CHEMBL288759 | {(1S,2R)-1-Benzyl-2-hydroxy-3-[(2R,...)
Show SMILES CC(C)(C)OC(=O)N[C@@H](Cc1ccccc1)[C@H](O)CNC[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@@](C)(O)C(C)(C)C
Show InChI InChI=1S/C32H49N3O6/c1-30(2,3)32(7,40)28(38)34-24(18-22-14-10-8-11-15-22)26(36)20-33-21-27(37)25(19-23-16-12-9-13-17-23)35-29(39)41-31(4,5)6/h8-17,24-27,33,36-37,40H,18-21H2,1-7H3,(H,34,38)(H,35,39)/t24-,25-,26+,27+,32+/m0/s1
PDB
MMDB

UniProtKB/TrEMBL

B.MOAD
DrugBank
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
24n/an/an/an/an/an/an/an/a



TBA

Curated by ChEMBL


Assay Description
Inhibition constant against HIV protease was determined


Bioorg Med Chem Lett 5: 1729-1734 (1995)


Article DOI: 10.1016/0960-894X(95)00293-3
BindingDB Entry DOI: 10.7270/Q2RN37TS
More data for this
Ligand-Target Pair
Coagulation factor XI


(Homo sapiens (Human))
BDBM50032858
PNG
(CHEMBL3355670)
Show SMILES OC(=O)C(F)(F)F.NC[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](Cc1ccccc1)c1nc(c[nH]1)-c1ccc(cc1)C(N)=O |r,wU:18.18,12.14,wD:9.7,(24.17,-9.75,;25.51,-10.52,;25.51,-12.06,;26.84,-9.75,;28.17,-10.52,;28.17,-8.96,;26.84,-8.21,;8.49,-17.32,;9.81,-18.09,;11.15,-17.33,;12.49,-18.1,;13.83,-17.34,;13.83,-15.79,;12.5,-15.03,;11.16,-15.79,;15.16,-15.02,;15.16,-13.48,;16.49,-15.79,;17.83,-15.02,;17.83,-13.48,;19.16,-12.71,;20.49,-13.49,;21.83,-12.72,;21.83,-11.18,;20.49,-10.41,;19.16,-11.18,;19.16,-15.79,;20.56,-15.17,;21.59,-16.31,;20.82,-17.65,;19.32,-17.32,;23.12,-16.15,;23.74,-14.75,;25.27,-14.59,;26.18,-15.83,;25.55,-17.24,;24.02,-17.4,;27.71,-15.67,;28.62,-16.91,;28.34,-14.26,)|
Show InChI InChI=1/C26H31N5O2.C2HF3O2/c27-15-18-6-8-21(9-7-18)26(33)31-22(14-17-4-2-1-3-5-17)25-29-16-23(30-25)19-10-12-20(13-11-19)24(28)32;3-2(4,5)1(6)7/h1-5,10-13,16,18,21-22H,6-9,14-15,27H2,(H2,28,32)(H,29,30)(H,31,33);(H,6,7)/t18-,21-,22-;/s2
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
Purchase

CHEMBL
MMDB
PC cid
PC sid
PDB
UniChem

Patents

Article
PubMed
30n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human coagulation factor 11a using p-nitroaniline as substrate assessed as substrate hydrolysis by spectrophotometrically


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM50032878
PNG
(CHEMBL3355679)
Show SMILES OC(=O)C(F)(F)F.NC[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](Cc1ccccc1)c1nc(c(Br)[nH]1)-c1ccc(cc1)C(N)=O |r,wU:18.18,12.14,wD:9.7,(29.77,-17.68,;31.11,-18.45,;31.11,-19.99,;32.44,-17.68,;33.78,-18.45,;33.77,-16.89,;32.44,-16.14,;13.69,-24.66,;15.02,-25.44,;16.36,-24.67,;17.7,-25.45,;19.04,-24.68,;19.03,-23.14,;17.7,-22.37,;16.36,-23.13,;20.36,-22.37,;20.36,-20.83,;21.69,-23.14,;23.03,-22.37,;23.03,-20.83,;24.37,-20.06,;25.7,-20.83,;27.03,-20.07,;27.03,-18.52,;25.69,-17.75,;24.36,-18.53,;24.36,-23.14,;25.77,-22.51,;26.8,-23.65,;26.03,-24.99,;26.66,-26.41,;24.52,-24.67,;28.32,-23.5,;28.94,-22.09,;30.47,-21.93,;31.39,-23.18,;30.76,-24.58,;29.23,-24.74,;32.92,-23.01,;33.83,-24.25,;33.55,-21.6,)|
Show InChI InChI=1/C26H30BrN5O2.C2HF3O2/c27-23-22(18-10-12-19(13-11-18)24(29)33)31-25(32-23)21(14-16-4-2-1-3-5-16)30-26(34)20-8-6-17(15-28)7-9-20;3-2(4,5)1(6)7/h1-5,10-13,17,20-21H,6-9,14-15,28H2,(H2,29,33)(H,30,34)(H,31,32);(H,6,7)/t17-,20-,21-;/s2
PDB

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
45n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-pNA as substrate


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM50032875
PNG
(CHEMBL3355682)
Show SMILES OC(=O)C(F)(F)F.NC[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](Cc1ccccc1)c1nc(c[nH]1)-c1ccc2c(N)n[nH]c2c1 |r,wU:12.14,wD:9.7,18.17,(39.15,-34.6,;40.47,-35.36,;40.47,-36.89,;41.79,-34.6,;43.11,-35.36,;41.79,-33.07,;43.11,-33.82,;26.66,-34.02,;27.43,-35.36,;26.66,-36.68,;25.12,-36.68,;24.35,-38.02,;25.12,-39.35,;26.66,-39.35,;27.43,-38.02,;24.35,-40.69,;22.81,-40.69,;25.12,-42.02,;24.35,-43.36,;22.81,-43.36,;22.04,-44.69,;22.81,-46.02,;22.04,-47.35,;20.5,-47.35,;19.73,-46.02,;20.5,-44.69,;25.12,-44.69,;26.65,-44.85,;26.97,-46.36,;25.64,-47.13,;24.49,-46.1,;28.38,-46.98,;28.54,-48.51,;29.95,-49.15,;31.19,-48.24,;32.7,-48.56,;33.32,-49.96,;33.47,-47.22,;32.44,-46.08,;31.03,-46.71,;29.63,-46.08,)|
Show InChI InChI=1/C26H31N7O.C2HF3O2/c27-14-17-6-8-18(9-7-17)26(34)31-22(12-16-4-2-1-3-5-16)25-29-15-23(30-25)19-10-11-20-21(13-19)32-33-24(20)28;3-2(4,5)1(6)7/h1-5,10-11,13,15,17-18,22H,6-9,12,14,27H2,(H,29,30)(H,31,34)(H3,28,32,33);(H,6,7)/t17-,18-,22-;/s2
PDB

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
50n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-pNA as substrate


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM50032858
PNG
(CHEMBL3355670)
Show SMILES OC(=O)C(F)(F)F.NC[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](Cc1ccccc1)c1nc(c[nH]1)-c1ccc(cc1)C(N)=O |r,wU:18.18,12.14,wD:9.7,(24.17,-9.75,;25.51,-10.52,;25.51,-12.06,;26.84,-9.75,;28.17,-10.52,;28.17,-8.96,;26.84,-8.21,;8.49,-17.32,;9.81,-18.09,;11.15,-17.33,;12.49,-18.1,;13.83,-17.34,;13.83,-15.79,;12.5,-15.03,;11.16,-15.79,;15.16,-15.02,;15.16,-13.48,;16.49,-15.79,;17.83,-15.02,;17.83,-13.48,;19.16,-12.71,;20.49,-13.49,;21.83,-12.72,;21.83,-11.18,;20.49,-10.41,;19.16,-11.18,;19.16,-15.79,;20.56,-15.17,;21.59,-16.31,;20.82,-17.65,;19.32,-17.32,;23.12,-16.15,;23.74,-14.75,;25.27,-14.59,;26.18,-15.83,;25.55,-17.24,;24.02,-17.4,;27.71,-15.67,;28.62,-16.91,;28.34,-14.26,)|
Show InChI InChI=1/C26H31N5O2.C2HF3O2/c27-15-18-6-8-21(9-7-18)26(33)31-22(14-17-4-2-1-3-5-17)25-29-16-23(30-25)19-10-12-20(13-11-19)24(28)32;3-2(4,5)1(6)7/h1-5,10-13,16,18,21-22H,6-9,14-15,27H2,(H2,28,32)(H,29,30)(H,31,33);(H,6,7)/t18-,21-,22-;/s2
PDB

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
Purchase

CHEMBL
MMDB
PC cid
PC sid
PDB
UniChem

Patents

Article
PubMed
60n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-pNA as substrate


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
HIV-1 Protease


(Human immunodeficiency virus type 1)
BDBM914
PNG
(Aminodiol deriv. 9a | BMS-186318 analog 1 | [(S,R)...)
Show SMILES CC(C)(C)OC(=O)N[C@@H](Cc1ccccc1)[C@H](O)CNC[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OC(C)(C)C |r|
Show InChI InChI=1S/C30H45N3O6/c1-29(2,3)38-27(36)32-23(17-21-13-9-7-10-14-21)25(34)19-31-20-26(35)24(18-22-15-11-8-12-16-22)33-28(37)39-30(4,5)6/h7-16,23-26,31,34-35H,17-20H2,1-6H3,(H,32,36)(H,33,37)/t23-,24-,25+,26+/m0/s1
PDB
MMDB

UniProtKB/TrEMBL

B.MOAD
GoogleScholar
AffyNet 
MMDB
PC cid
PC sid
PDB
UniChem
PDB
Article
PubMed
100 -41.6 125n/an/an/an/a5.537



Bristol-Myers Squibb Company



Assay Description
Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...


J Med Chem 37: 1758-68 (1994)


Article DOI: 10.1016/j.bmcl.2004.02.008
BindingDB Entry DOI: 10.7270/Q257196C
More data for this
Ligand-Target Pair
3D
3D Structure (crystal)
Human immunodeficiency virus type 1 protease


(Human immunodeficiency virus type 1)
BDBM914
PNG
(Aminodiol deriv. 9a | BMS-186318 analog 1 | [(S,R)...)
Show SMILES CC(C)(C)OC(=O)N[C@@H](Cc1ccccc1)[C@H](O)CNC[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OC(C)(C)C |r|
Show InChI InChI=1S/C30H45N3O6/c1-29(2,3)38-27(36)32-23(17-21-13-9-7-10-14-21)25(34)19-31-20-26(35)24(18-22-15-11-8-12-16-22)33-28(37)39-30(4,5)6/h7-16,23-26,31,34-35H,17-20H2,1-6H3,(H,32,36)(H,33,37)/t23-,24-,25+,26+/m0/s1
PDB
MMDB

UniProtKB/TrEMBL

B.MOAD
DrugBank
GoogleScholar
AffyNet 
MMDB
PC cid
PC sid
PDB
UniChem
PDB
Article
100n/an/an/an/an/an/an/an/a



TBA

Curated by ChEMBL


Assay Description
In vitro inhibition of HIV-1 protease.


Bioorg Med Chem Lett 5: 1729-1734 (1995)


Article DOI: 10.1016/0960-894X(95)00293-3
BindingDB Entry DOI: 10.7270/Q2RN37TS
More data for this
Ligand-Target Pair
3D
3D Structure (crystal)
Coagulation factor XI


(Homo sapiens (Human))
BDBM50032866
PNG
(CHEMBL3355664)
Show SMILES OC(=O)C(F)(F)F.NC[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](Cc1ccccc1)c1nc(c[nH]1)-c1ccccc1 |r,wU:18.18,12.14,wD:9.7,(25.97,-5.14,;27.3,-5.91,;27.3,-7.45,;28.64,-5.14,;29.97,-5.91,;29.96,-4.35,;28.64,-3.6,;10.28,-12.71,;11.61,-13.48,;12.94,-12.72,;14.28,-13.49,;15.62,-12.73,;15.62,-11.18,;14.29,-10.41,;12.95,-11.18,;16.95,-10.41,;16.95,-8.87,;18.28,-11.18,;19.62,-10.41,;19.62,-8.87,;20.96,-8.1,;22.29,-8.88,;23.62,-8.11,;23.62,-6.57,;22.28,-5.8,;20.95,-6.57,;20.95,-11.18,;22.36,-10.56,;23.39,-11.7,;22.62,-13.04,;21.11,-12.71,;24.92,-11.54,;25.54,-10.13,;27.06,-9.97,;27.98,-11.22,;27.35,-12.63,;25.82,-12.79,)|
Show InChI InChI=1/C25H30N4O/c26-16-19-11-13-21(14-12-19)25(30)29-22(15-18-7-3-1-4-8-18)24-27-17-23(28-24)20-9-5-2-6-10-20/h1-10,17,19,21-22H,11-16,26H2,(H,27,28)(H,29,30)/t19-,21-,22-/s2
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Patents

Article
PubMed
120n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human coagulation factor 11a using p-nitroaniline as substrate assessed as substrate hydrolysis by spectrophotometrically


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Coagulation factor XI


(Homo sapiens (Human))
BDBM50032883
PNG
(CHEMBL3355674)
Show SMILES OC(=O)C(F)(F)F.NC[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](Cc1ccccc1)c1nc(c[nH]1)-c1ccc(CC(O)=O)cc1 |r,wU:18.18,12.14,wD:9.7,(29.77,-17.68,;31.11,-18.45,;31.11,-19.99,;32.44,-17.68,;33.77,-18.45,;33.77,-16.89,;32.44,-16.14,;13.69,-24.66,;15.02,-25.44,;16.35,-24.67,;17.7,-25.45,;19.03,-24.68,;19.03,-23.14,;17.7,-22.37,;16.36,-23.13,;20.36,-22.37,;20.36,-20.83,;21.69,-23.14,;23.03,-22.37,;23.03,-20.83,;24.37,-20.06,;25.7,-20.83,;27.03,-20.06,;27.03,-18.52,;25.69,-17.75,;24.36,-18.52,;24.36,-23.14,;25.76,-22.51,;26.8,-23.65,;26.03,-24.99,;24.52,-24.67,;28.32,-23.5,;28.94,-22.09,;30.47,-21.93,;31.38,-23.17,;32.92,-23.01,;33.82,-24.25,;33.2,-25.67,;35.36,-24.09,;30.76,-24.58,;29.23,-24.74,)|
Show InChI InChI=1/C27H32N4O3.C2HF3O2/c28-16-20-8-12-22(13-9-20)27(34)31-23(14-18-4-2-1-3-5-18)26-29-17-24(30-26)21-10-6-19(7-11-21)15-25(32)33;3-2(4,5)1(6)7/h1-7,10-11,17,20,22-23H,8-9,12-16,28H2,(H,29,30)(H,31,34)(H,32,33);(H,6,7)/t20-,22-,23-;/s2
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
150n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human coagulation factor 11a using p-nitroaniline as substrate assessed as substrate hydrolysis by spectrophotometrically


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM50032885
PNG
(CHEMBL3355672)
Show SMILES OC(=O)C(F)(F)F.CNC(=O)c1ccc(cc1)-c1c[nH]c(n1)[C@H](Cc1ccccc1)NC(=O)[C@H]1CC[C@H](CN)CC1 |r,wU:22.23,33.34,wD:36.38,(24.46,-10.74,;25.79,-11.51,;25.79,-13.05,;27.12,-10.74,;28.46,-11.51,;28.45,-9.95,;27.12,-9.2,;27.89,-18.72,;28.51,-17.31,;27.6,-16.07,;28.22,-14.66,;26.07,-16.23,;25.15,-14.99,;23.63,-15.15,;23.01,-16.56,;23.91,-17.8,;25.44,-17.64,;21.48,-16.71,;20.71,-18.05,;19.21,-17.73,;19.05,-16.2,;20.45,-15.57,;17.72,-15.43,;17.72,-13.89,;19.05,-13.12,;20.38,-13.89,;21.72,-13.12,;21.72,-11.58,;20.37,-10.81,;19.05,-11.58,;16.38,-16.2,;15.05,-15.43,;15.05,-13.89,;13.72,-16.2,;13.72,-17.74,;12.38,-18.51,;11.04,-17.73,;9.7,-18.5,;8.38,-17.72,;11.05,-16.19,;12.39,-15.43,)|
Show InChI InChI=1/C27H33N5O2.C2HF3O2/c1-29-26(33)21-13-11-20(12-14-21)24-17-30-25(31-24)23(15-18-5-3-2-4-6-18)32-27(34)22-9-7-19(16-28)8-10-22;3-2(4,5)1(6)7/h2-6,11-14,17,19,22-23H,7-10,15-16,28H2,1H3,(H,29,33)(H,30,31)(H,32,34);(H,6,7)/t19-,22-,23-;/s2
PDB

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
220n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-pNA as substrate


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Coagulation factor XI


(Homo sapiens (Human))
BDBM50032865
PNG
(CHEMBL3355665)
Show SMILES OC(=O)C(F)(F)F.NC[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](Cc1ccccc1)c1nc(c[nH]1)-c1ccc(cc1)C#N |r,wU:18.18,12.14,wD:9.7,(25.97,-5.14,;27.3,-5.91,;27.3,-7.45,;28.64,-5.14,;29.97,-5.91,;29.96,-4.35,;28.64,-3.6,;10.28,-12.71,;11.61,-13.48,;12.94,-12.72,;14.28,-13.49,;15.62,-12.73,;15.62,-11.18,;14.29,-10.41,;12.95,-11.18,;16.95,-10.41,;16.95,-8.87,;18.28,-11.18,;19.62,-10.41,;19.62,-8.87,;20.96,-8.1,;22.29,-8.88,;23.62,-8.11,;23.62,-6.57,;22.28,-5.8,;20.95,-6.57,;20.95,-11.18,;22.36,-10.56,;23.39,-11.7,;22.62,-13.04,;21.11,-12.71,;24.92,-11.54,;25.54,-10.13,;27.06,-9.97,;27.98,-11.22,;27.35,-12.63,;25.82,-12.79,;29.5,-11.05,;31.03,-10.89,)|
Show InChI InChI=1/C26H29N5O/c27-15-19-6-10-21(11-7-19)24-17-29-25(30-24)23(14-18-4-2-1-3-5-18)31-26(32)22-12-8-20(16-28)9-13-22/h1-7,10-11,17,20,22-23H,8-9,12-14,16,28H2,(H,29,30)(H,31,32)/t20-,22-,23-/s2
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Patents

Article
PubMed
230n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human coagulation factor 11a using p-nitroaniline as substrate assessed as substrate hydrolysis by spectrophotometrically


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Coagulation factor XI


(Homo sapiens (Human))
BDBM50032880
PNG
(CHEMBL3355677)
Show SMILES OC(=O)C(F)(F)F.NC[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](Cc1ccccc1)c1nc(c[nH]1)-c1cccc(CC(O)=O)c1 |r,wU:18.18,12.14,wD:9.7,(29.77,-17.68,;31.11,-18.45,;31.11,-19.99,;32.44,-17.68,;33.78,-18.45,;33.77,-16.89,;32.44,-16.14,;13.69,-24.66,;15.02,-25.44,;16.36,-24.67,;17.7,-25.45,;19.04,-24.68,;19.03,-23.14,;17.7,-22.37,;16.36,-23.13,;20.36,-22.37,;20.36,-20.83,;21.69,-23.14,;23.03,-22.37,;23.03,-20.83,;24.37,-20.06,;25.7,-20.83,;27.03,-20.07,;27.03,-18.52,;25.69,-17.75,;24.36,-18.53,;24.36,-23.14,;25.77,-22.51,;26.8,-23.65,;26.03,-24.99,;24.52,-24.67,;28.32,-23.5,;28.94,-22.09,;30.47,-21.93,;31.39,-23.18,;30.76,-24.58,;31.67,-25.83,;31.04,-27.24,;29.51,-27.41,;31.95,-28.49,;29.23,-24.74,)|
Show InChI InChI=1/C27H32N4O3.C2HF3O2/c28-16-19-9-11-21(12-10-19)27(34)31-23(14-18-5-2-1-3-6-18)26-29-17-24(30-26)22-8-4-7-20(13-22)15-25(32)33;3-2(4,5)1(6)7/h1-8,13,17,19,21,23H,9-12,14-16,28H2,(H,29,30)(H,31,34)(H,32,33);(H,6,7)/t19-,21-,23-;/s2
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
275n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human coagulation factor 11a using p-nitroaniline as substrate assessed as substrate hydrolysis by spectrophotometrically


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM50032866
PNG
(CHEMBL3355664)
Show SMILES OC(=O)C(F)(F)F.NC[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](Cc1ccccc1)c1nc(c[nH]1)-c1ccccc1 |r,wU:18.18,12.14,wD:9.7,(25.97,-5.14,;27.3,-5.91,;27.3,-7.45,;28.64,-5.14,;29.97,-5.91,;29.96,-4.35,;28.64,-3.6,;10.28,-12.71,;11.61,-13.48,;12.94,-12.72,;14.28,-13.49,;15.62,-12.73,;15.62,-11.18,;14.29,-10.41,;12.95,-11.18,;16.95,-10.41,;16.95,-8.87,;18.28,-11.18,;19.62,-10.41,;19.62,-8.87,;20.96,-8.1,;22.29,-8.88,;23.62,-8.11,;23.62,-6.57,;22.28,-5.8,;20.95,-6.57,;20.95,-11.18,;22.36,-10.56,;23.39,-11.7,;22.62,-13.04,;21.11,-12.71,;24.92,-11.54,;25.54,-10.13,;27.06,-9.97,;27.98,-11.22,;27.35,-12.63,;25.82,-12.79,)|
Show InChI InChI=1/C25H30N4O/c26-16-19-11-13-21(14-12-19)25(30)29-22(15-18-7-3-1-4-8-18)24-27-17-23(28-24)20-9-5-2-6-10-20/h1-10,17,19,21-22H,11-16,26H2,(H,27,28)(H,29,30)/t19-,21-,22-/s2
PDB

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Patents

Article
PubMed
330n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-pNA as substrate


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Coagulation factor X


(Homo sapiens (Human))
BDBM50448583
PNG
(CHEMBL3127491)
Show SMILES CC(C)CC(=O)Nc1cc(cc(c1)-c1ccc(cc1C(O)=O)C(N)=O)[C@@H]1C[C@](C)(c2ccccc2)c2cc(ccc2N1)C(N)=N |r|
Show InChI InChI=1S/C36H37N5O4/c1-20(2)13-32(42)40-26-15-23(27-11-9-22(34(39)43)17-28(27)35(44)45)14-24(16-26)31-19-36(3,25-7-5-4-6-8-25)29-18-21(33(37)38)10-12-30(29)41-31/h4-12,14-18,20,31,41H,13,19H2,1-3H3,(H3,37,38)(H2,39,43)(H,40,42)(H,44,45)/t31-,36+/m0/s1
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
PDB
UniChem
Article
PubMed
340n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human coagulation factor 10a using N-benzoyl-Ile-Glu-(OH, OMe)-Gly-Arg-pNA as substrate by spectrophotometric analysis


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Coagulation factor XI


(Homo sapiens (Human))
BDBM50032885
PNG
(CHEMBL3355672)
Show SMILES OC(=O)C(F)(F)F.CNC(=O)c1ccc(cc1)-c1c[nH]c(n1)[C@H](Cc1ccccc1)NC(=O)[C@H]1CC[C@H](CN)CC1 |r,wU:22.23,33.34,wD:36.38,(24.46,-10.74,;25.79,-11.51,;25.79,-13.05,;27.12,-10.74,;28.46,-11.51,;28.45,-9.95,;27.12,-9.2,;27.89,-18.72,;28.51,-17.31,;27.6,-16.07,;28.22,-14.66,;26.07,-16.23,;25.15,-14.99,;23.63,-15.15,;23.01,-16.56,;23.91,-17.8,;25.44,-17.64,;21.48,-16.71,;20.71,-18.05,;19.21,-17.73,;19.05,-16.2,;20.45,-15.57,;17.72,-15.43,;17.72,-13.89,;19.05,-13.12,;20.38,-13.89,;21.72,-13.12,;21.72,-11.58,;20.37,-10.81,;19.05,-11.58,;16.38,-16.2,;15.05,-15.43,;15.05,-13.89,;13.72,-16.2,;13.72,-17.74,;12.38,-18.51,;11.04,-17.73,;9.7,-18.5,;8.38,-17.72,;11.05,-16.19,;12.39,-15.43,)|
Show InChI InChI=1/C27H33N5O2.C2HF3O2/c1-29-26(33)21-13-11-20(12-14-21)24-17-30-25(31-24)23(15-18-5-3-2-4-6-18)32-27(34)22-9-7-19(16-28)8-10-22;3-2(4,5)1(6)7/h2-6,11-14,17,19,22-23H,7-10,15-16,28H2,1H3,(H,29,33)(H,30,31)(H,32,34);(H,6,7)/t19-,22-,23-;/s2
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
350n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human coagulation factor 11a using p-nitroaniline as substrate assessed as substrate hydrolysis by spectrophotometrically


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Coagulation factor XI


(Homo sapiens (Human))
BDBM50032882
PNG
(CHEMBL3355675)
Show SMILES OC(=O)C(F)(F)F.NC[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](Cc1ccccc1)c1nc(c[nH]1)-c1ccc(CC(N)=O)cc1 |r,wU:18.18,12.14,wD:9.7,(29.77,-17.68,;31.11,-18.45,;31.11,-19.99,;32.44,-17.68,;33.77,-18.45,;33.77,-16.89,;32.44,-16.14,;13.69,-24.66,;15.02,-25.44,;16.35,-24.67,;17.7,-25.45,;19.03,-24.68,;19.03,-23.14,;17.7,-22.37,;16.36,-23.13,;20.36,-22.37,;20.36,-20.83,;21.69,-23.14,;23.03,-22.37,;23.03,-20.83,;24.37,-20.06,;25.7,-20.83,;27.03,-20.06,;27.03,-18.52,;25.69,-17.75,;24.36,-18.52,;24.36,-23.14,;25.76,-22.51,;26.8,-23.65,;26.03,-24.99,;24.52,-24.67,;28.32,-23.5,;28.94,-22.09,;30.47,-21.93,;31.38,-23.17,;32.92,-23.01,;33.82,-24.25,;33.2,-25.67,;35.36,-24.09,;30.76,-24.58,;29.23,-24.74,)|
Show InChI InChI=1/C27H33N5O2.C2HF3O2/c28-16-20-8-12-22(13-9-20)27(34)32-23(14-18-4-2-1-3-5-18)26-30-17-24(31-26)21-10-6-19(7-11-21)15-25(29)33;3-2(4,5)1(6)7/h1-7,10-11,17,20,22-23H,8-9,12-16,28H2,(H2,29,33)(H,30,31)(H,32,34);(H,6,7)/t20-,22-,23-;/s2
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Patents

Article
PubMed
400n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human coagulation factor 11a using p-nitroaniline as substrate assessed as substrate hydrolysis by spectrophotometrically


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Coagulation factor XI


(Homo sapiens (Human))
BDBM50032863
PNG
(CHEMBL3355667)
Show SMILES OC(=O)C(F)(F)F.CCOC(=O)Cc1ccc(cc1)-c1c[nH]c(n1)[C@H](Cc1ccccc1)NC(=O)[C@H]1CC[C@H](CN)CC1 |r,wU:24.25,35.36,wD:38.40,(24.99,-5.26,;26.33,-6.03,;26.33,-7.58,;27.66,-5.26,;28.99,-6.03,;28.99,-4.47,;27.66,-3.72,;33.41,-13.3,;31.88,-13.47,;30.97,-12.23,;29.44,-12.41,;28.82,-13.82,;28.53,-11.17,;27,-11.34,;26.09,-10.1,;24.56,-10.26,;23.94,-11.67,;24.84,-12.91,;26.37,-12.75,;22.41,-11.82,;21.64,-13.16,;20.14,-12.84,;19.98,-11.31,;21.38,-10.68,;18.65,-10.54,;18.65,-9,;19.98,-8.23,;21.31,-9,;22.65,-8.23,;22.65,-6.69,;21.31,-5.92,;19.98,-6.69,;17.31,-11.31,;15.98,-10.54,;15.98,-9,;14.64,-11.31,;14.65,-12.85,;13.31,-13.62,;11.97,-12.84,;10.63,-13.61,;9.31,-12.83,;11.98,-11.3,;13.32,-10.54,)|
Show InChI InChI=1/C29H36N4O3.C2HF3O2/c1-2-36-27(34)17-21-8-12-23(13-9-21)26-19-31-28(32-26)25(16-20-6-4-3-5-7-20)33-29(35)24-14-10-22(18-30)11-15-24;3-2(4,5)1(6)7/h3-9,12-13,19,22,24-25H,2,10-11,14-18,30H2,1H3,(H,31,32)(H,33,35);(H,6,7)/t22-,24-,25-;/s2
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Patents

Article
PubMed
495n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human coagulation factor 11a using p-nitroaniline as substrate assessed as substrate hydrolysis by spectrophotometrically


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Coagulation factor XI


(Homo sapiens (Human))
BDBM50032879
PNG
(CHEMBL3355678)
Show SMILES OC(=O)C(F)(F)F.NC[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](Cc1ccccc1)c1nc(c[nH]1)-c1cccc(CC(N)=O)c1 |r,wU:18.18,12.14,wD:9.7,(29.77,-17.68,;31.11,-18.45,;31.11,-19.99,;32.44,-17.68,;33.78,-18.45,;33.77,-16.89,;32.44,-16.14,;13.69,-24.66,;15.02,-25.44,;16.36,-24.67,;17.7,-25.45,;19.04,-24.68,;19.03,-23.14,;17.7,-22.37,;16.36,-23.13,;20.36,-22.37,;20.36,-20.83,;21.69,-23.14,;23.03,-22.37,;23.03,-20.83,;24.37,-20.06,;25.7,-20.83,;27.03,-20.07,;27.03,-18.52,;25.69,-17.75,;24.36,-18.53,;24.36,-23.14,;25.77,-22.51,;26.8,-23.65,;26.03,-24.99,;24.52,-24.67,;28.32,-23.5,;28.94,-22.09,;30.47,-21.93,;31.39,-23.18,;30.76,-24.58,;31.67,-25.83,;31.04,-27.24,;29.51,-27.41,;31.95,-28.49,;29.23,-24.74,)|
Show InChI InChI=1/C27H33N5O2.C2HF3O2/c28-16-19-9-11-21(12-10-19)27(34)32-23(14-18-5-2-1-3-6-18)26-30-17-24(31-26)22-8-4-7-20(13-22)15-25(29)33;3-2(4,5)1(6)7/h1-8,13,17,19,21,23H,9-12,14-16,28H2,(H2,29,33)(H,30,31)(H,32,34);(H,6,7)/t19-,21-,23-;/s2
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
545n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human coagulation factor 11a using p-nitroaniline as substrate assessed as substrate hydrolysis by spectrophotometrically


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Coagulation factor XI


(Homo sapiens (Human))
BDBM50032886
PNG
(CHEMBL3355671)
Show SMILES OC(=O)C(F)(F)F.NC[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](Cc1ccccc1)c1nc(c[nH]1)-c1ccc(cc1)C(O)=O |r,wU:18.18,12.14,wD:9.7,(24.46,-10.74,;25.79,-11.51,;25.79,-13.05,;27.12,-10.74,;28.46,-11.51,;28.45,-9.95,;27.12,-9.2,;8.38,-17.72,;9.7,-18.5,;11.04,-17.73,;12.38,-18.51,;13.72,-17.74,;13.72,-16.2,;12.39,-15.43,;11.05,-16.19,;15.05,-15.43,;15.05,-13.89,;16.38,-16.2,;17.72,-15.43,;17.72,-13.89,;19.05,-13.12,;20.38,-13.89,;21.72,-13.12,;21.72,-11.58,;20.37,-10.81,;19.05,-11.58,;19.05,-16.2,;20.45,-15.57,;21.48,-16.71,;20.71,-18.05,;19.21,-17.73,;23.01,-16.56,;23.63,-15.15,;25.15,-14.99,;26.07,-16.23,;25.44,-17.64,;23.91,-17.8,;27.6,-16.07,;28.51,-17.31,;28.22,-14.66,)|
Show InChI InChI=1/C26H30N4O3/c27-15-18-6-8-20(9-7-18)25(31)30-22(14-17-4-2-1-3-5-17)24-28-16-23(29-24)19-10-12-21(13-11-19)26(32)33/h1-5,10-13,16,18,20,22H,6-9,14-15,27H2,(H,28,29)(H,30,31)(H,32,33)/t18-,20-,22-/s2
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Patents

Article
PubMed
590n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human coagulation factor 11a using p-nitroaniline as substrate assessed as substrate hydrolysis by spectrophotometrically


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Coagulation factor XI


(Homo sapiens (Human))
BDBM50032860
PNG
(CHEMBL3355669)
Show SMILES OC(=O)C(F)(F)F.CCOC(=O)Cc1cccc(c1)-c1c[nH]c(n1)[C@H](Cc1ccccc1)NC(=O)[C@H]1CC[C@H](CN)CC1 |r,wU:24.25,35.36,wD:38.40,(24.99,-5.26,;26.32,-6.03,;26.32,-7.58,;27.66,-5.26,;28.99,-6.03,;28.98,-4.47,;27.66,-3.72,;27.86,-19.29,;26.95,-18.05,;27.57,-16.64,;26.66,-15.4,;25.13,-15.56,;27.28,-13.99,;26.37,-12.75,;27,-11.34,;26.08,-10.1,;24.56,-10.26,;23.94,-11.66,;24.84,-12.91,;22.41,-11.82,;21.64,-13.16,;20.13,-12.83,;19.98,-11.31,;21.38,-10.68,;18.64,-10.54,;18.64,-9,;19.98,-8.23,;21.31,-9,;22.64,-8.23,;22.65,-6.69,;21.3,-5.92,;19.97,-6.69,;17.31,-11.3,;15.97,-10.53,;15.97,-8.99,;14.64,-11.3,;14.65,-12.85,;13.31,-13.61,;11.97,-12.84,;10.63,-13.6,;9.3,-12.83,;11.97,-11.3,;13.31,-10.54,)|
Show InChI InChI=1/C29H36N4O3.C2HF3O2/c1-2-36-27(34)17-22-9-6-10-24(15-22)26-19-31-28(32-26)25(16-20-7-4-3-5-8-20)33-29(35)23-13-11-21(18-30)12-14-23;3-2(4,5)1(6)7/h3-10,15,19,21,23,25H,2,11-14,16-18,30H2,1H3,(H,31,32)(H,33,35);(H,6,7)/t21-,23-,25-;/s2
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
Purchase

CHEMBL
MMDB
PC cid
PC sid
PDB
UniChem

Patents

Article
PubMed
630n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human coagulation factor 11a using p-nitroaniline as substrate assessed as substrate hydrolysis by spectrophotometrically


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Coagulation factor VII


(Homo sapiens (Human))
BDBM50448583
PNG
(CHEMBL3127491)
Show SMILES CC(C)CC(=O)Nc1cc(cc(c1)-c1ccc(cc1C(O)=O)C(N)=O)[C@@H]1C[C@](C)(c2ccccc2)c2cc(ccc2N1)C(N)=N |r|
Show InChI InChI=1S/C36H37N5O4/c1-20(2)13-32(42)40-26-15-23(27-11-9-22(34(39)43)17-28(27)35(44)45)14-24(16-26)31-19-36(3,25-7-5-4-6-8-25)29-18-21(33(37)38)10-12-30(29)41-31/h4-12,14-18,20,31,41H,13,19H2,1-3H3,(H3,37,38)(H2,39,43)(H,40,42)(H,44,45)/t31-,36+/m0/s1
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
PDB
UniChem
Article
PubMed
630n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human coagulation factor 7a using H-(D)-Ile-Pro-Arg-pNA as substrate by spectrophotometric analysis


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM50032883
PNG
(CHEMBL3355674)
Show SMILES OC(=O)C(F)(F)F.NC[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](Cc1ccccc1)c1nc(c[nH]1)-c1ccc(CC(O)=O)cc1 |r,wU:18.18,12.14,wD:9.7,(29.77,-17.68,;31.11,-18.45,;31.11,-19.99,;32.44,-17.68,;33.77,-18.45,;33.77,-16.89,;32.44,-16.14,;13.69,-24.66,;15.02,-25.44,;16.35,-24.67,;17.7,-25.45,;19.03,-24.68,;19.03,-23.14,;17.7,-22.37,;16.36,-23.13,;20.36,-22.37,;20.36,-20.83,;21.69,-23.14,;23.03,-22.37,;23.03,-20.83,;24.37,-20.06,;25.7,-20.83,;27.03,-20.06,;27.03,-18.52,;25.69,-17.75,;24.36,-18.52,;24.36,-23.14,;25.76,-22.51,;26.8,-23.65,;26.03,-24.99,;24.52,-24.67,;28.32,-23.5,;28.94,-22.09,;30.47,-21.93,;31.38,-23.17,;32.92,-23.01,;33.82,-24.25,;33.2,-25.67,;35.36,-24.09,;30.76,-24.58,;29.23,-24.74,)|
Show InChI InChI=1/C27H32N4O3.C2HF3O2/c28-16-20-8-12-22(13-9-20)27(34)31-23(14-18-4-2-1-3-5-18)26-29-17-24(30-26)21-10-6-19(7-11-21)15-25(32)33;3-2(4,5)1(6)7/h1-7,10-11,17,20,22-23H,8-9,12-16,28H2,(H,29,30)(H,31,34)(H,32,33);(H,6,7)/t20-,22-,23-;/s2
PDB

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
765n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-pNA as substrate


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Coagulation factor XI


(Homo sapiens (Human))
BDBM50032864
PNG
(CHEMBL3355666)
Show SMILES OC(=O)C(F)(F)F.COC(=O)c1ccc(cc1)-c1c[nH]c(n1)[C@H](Cc1ccccc1)NC(=O)[C@H]1CC[C@H](CN)CC1 |r,wU:22.23,33.34,wD:36.38,(24.99,-5.26,;26.33,-6.03,;26.33,-7.58,;27.66,-5.26,;28.99,-6.03,;28.99,-4.47,;27.66,-3.72,;28.82,-13.82,;29.44,-12.41,;28.53,-11.17,;29.14,-9.77,;27,-11.34,;26.09,-10.1,;24.56,-10.26,;23.94,-11.67,;24.84,-12.91,;26.37,-12.75,;22.41,-11.82,;21.64,-13.16,;20.14,-12.84,;19.98,-11.31,;21.38,-10.68,;18.65,-10.54,;18.65,-9,;19.98,-8.23,;21.31,-9,;22.65,-8.23,;22.65,-6.69,;21.31,-5.92,;19.98,-6.69,;17.31,-11.31,;15.98,-10.54,;15.98,-9,;14.64,-11.31,;14.65,-12.85,;13.31,-13.62,;11.97,-12.84,;10.63,-13.61,;9.31,-12.83,;11.98,-11.3,;13.32,-10.54,)|
Show InChI InChI=1/C27H32N4O3/c1-34-27(33)22-13-11-20(12-14-22)24-17-29-25(30-24)23(15-18-5-3-2-4-6-18)31-26(32)21-9-7-19(16-28)8-10-21/h2-6,11-14,17,19,21,23H,7-10,15-16,28H2,1H3,(H,29,30)(H,31,32)/t19-,21-,23-/s2
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
MMDB
PC cid
PC sid
UniChem

Patents

Article
PubMed
800n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human coagulation factor 11a using p-nitroaniline as substrate assessed as substrate hydrolysis by spectrophotometrically


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM50032881
PNG
(CHEMBL3355676)
Show SMILES OC(=O)C(F)(F)F.NC[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](Cc1ccccc1)c1nc(c[nH]1)-c1cccc(c1)C(N)=O |r,wU:18.18,12.14,wD:9.7,(29.77,-17.68,;31.11,-18.45,;31.11,-19.99,;32.44,-17.68,;33.78,-18.45,;33.77,-16.89,;32.44,-16.14,;13.69,-24.66,;15.02,-25.44,;16.36,-24.67,;17.7,-25.45,;19.04,-24.68,;19.03,-23.14,;17.7,-22.37,;16.36,-23.13,;20.36,-22.37,;20.36,-20.83,;21.69,-23.14,;23.03,-22.37,;23.03,-20.83,;24.37,-20.06,;25.7,-20.83,;27.03,-20.07,;27.03,-18.52,;25.69,-17.75,;24.36,-18.53,;24.36,-23.14,;25.77,-22.51,;26.8,-23.65,;26.03,-24.99,;24.52,-24.67,;28.32,-23.5,;28.94,-22.09,;30.47,-21.93,;31.39,-23.18,;30.76,-24.58,;29.23,-24.74,;31.67,-25.83,;31.04,-27.24,;33.2,-25.67,)|
Show InChI InChI=1/C26H31N5O2.C2HF3O2/c27-15-18-9-11-19(12-10-18)26(33)31-22(13-17-5-2-1-3-6-17)25-29-16-23(30-25)20-7-4-8-21(14-20)24(28)32;3-2(4,5)1(6)7/h1-8,14,16,18-19,22H,9-13,15,27H2,(H2,28,32)(H,29,30)(H,31,33);(H,6,7)/t18-,19-,22-;/s2
PDB

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
910n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-pNA as substrate


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM50032880
PNG
(CHEMBL3355677)
Show SMILES OC(=O)C(F)(F)F.NC[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](Cc1ccccc1)c1nc(c[nH]1)-c1cccc(CC(O)=O)c1 |r,wU:18.18,12.14,wD:9.7,(29.77,-17.68,;31.11,-18.45,;31.11,-19.99,;32.44,-17.68,;33.78,-18.45,;33.77,-16.89,;32.44,-16.14,;13.69,-24.66,;15.02,-25.44,;16.36,-24.67,;17.7,-25.45,;19.04,-24.68,;19.03,-23.14,;17.7,-22.37,;16.36,-23.13,;20.36,-22.37,;20.36,-20.83,;21.69,-23.14,;23.03,-22.37,;23.03,-20.83,;24.37,-20.06,;25.7,-20.83,;27.03,-20.07,;27.03,-18.52,;25.69,-17.75,;24.36,-18.53,;24.36,-23.14,;25.77,-22.51,;26.8,-23.65,;26.03,-24.99,;24.52,-24.67,;28.32,-23.5,;28.94,-22.09,;30.47,-21.93,;31.39,-23.18,;30.76,-24.58,;31.67,-25.83,;31.04,-27.24,;29.51,-27.41,;31.95,-28.49,;29.23,-24.74,)|
Show InChI InChI=1/C27H32N4O3.C2HF3O2/c28-16-19-9-11-21(12-10-19)27(34)31-23(14-18-5-2-1-3-6-18)26-29-17-24(30-26)22-8-4-7-20(13-22)15-25(32)33;3-2(4,5)1(6)7/h1-8,13,17,19,21,23H,9-12,14-16,28H2,(H,29,30)(H,31,34)(H,32,33);(H,6,7)/t19-,21-,23-;/s2
PDB

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
920n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-pNA as substrate


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM50032865
PNG
(CHEMBL3355665)
Show SMILES OC(=O)C(F)(F)F.NC[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](Cc1ccccc1)c1nc(c[nH]1)-c1ccc(cc1)C#N |r,wU:18.18,12.14,wD:9.7,(25.97,-5.14,;27.3,-5.91,;27.3,-7.45,;28.64,-5.14,;29.97,-5.91,;29.96,-4.35,;28.64,-3.6,;10.28,-12.71,;11.61,-13.48,;12.94,-12.72,;14.28,-13.49,;15.62,-12.73,;15.62,-11.18,;14.29,-10.41,;12.95,-11.18,;16.95,-10.41,;16.95,-8.87,;18.28,-11.18,;19.62,-10.41,;19.62,-8.87,;20.96,-8.1,;22.29,-8.88,;23.62,-8.11,;23.62,-6.57,;22.28,-5.8,;20.95,-6.57,;20.95,-11.18,;22.36,-10.56,;23.39,-11.7,;22.62,-13.04,;21.11,-12.71,;24.92,-11.54,;25.54,-10.13,;27.06,-9.97,;27.98,-11.22,;27.35,-12.63,;25.82,-12.79,;29.5,-11.05,;31.03,-10.89,)|
Show InChI InChI=1/C26H29N5O/c27-15-19-6-10-21(11-7-19)24-17-29-25(30-24)23(14-18-4-2-1-3-5-18)31-26(32)22-12-8-20(16-28)9-13-22/h1-7,10-11,17,20,22-23H,8-9,12-14,16,28H2,(H,29,30)(H,31,32)/t20-,22-,23-/s2
PDB

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Patents

Article
PubMed
940n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-pNA as substrate


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Coagulation factor XI


(Homo sapiens (Human))
BDBM50032871
PNG
(CHEMBL3355686)
Show SMILES NC[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](Cc1ccccc1)c1nc(n[nH]1)-c1ccccc1 |r,wU:5.8,wD:11.11,2.1,(31.04,-42.98,;29.71,-43.75,;28.38,-42.98,;28.38,-41.44,;27.04,-40.67,;25.71,-41.44,;25.71,-42.98,;27.04,-43.75,;24.37,-40.67,;24.37,-39.13,;23.04,-41.44,;21.7,-40.67,;21.7,-39.13,;20.37,-38.36,;19.04,-39.13,;17.71,-38.36,;17.71,-36.82,;19.04,-36.05,;20.37,-36.82,;20.41,-41.51,;18.98,-40.96,;18.01,-42.15,;18.84,-43.44,;20.33,-43.05,;16.47,-42.07,;15.63,-43.36,;14.09,-43.28,;13.4,-41.91,;14.23,-40.62,;15.77,-40.7,)|
Show InChI InChI=1/C24H29N5O/c25-16-18-11-13-20(14-12-18)24(30)26-21(15-17-7-3-1-4-8-17)23-27-22(28-29-23)19-9-5-2-6-10-19/h1-10,18,20-21H,11-16,25H2,(H,26,30)(H,27,28,29)/t18-,20-,21-/s2
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
980n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human coagulation factor 11a using p-nitroaniline as substrate assessed as substrate hydrolysis by spectrophotometrically


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Coagulation factor XI


(Homo sapiens (Human))
BDBM50032881
PNG
(CHEMBL3355676)
Show SMILES OC(=O)C(F)(F)F.NC[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](Cc1ccccc1)c1nc(c[nH]1)-c1cccc(c1)C(N)=O |r,wU:18.18,12.14,wD:9.7,(29.77,-17.68,;31.11,-18.45,;31.11,-19.99,;32.44,-17.68,;33.78,-18.45,;33.77,-16.89,;32.44,-16.14,;13.69,-24.66,;15.02,-25.44,;16.36,-24.67,;17.7,-25.45,;19.04,-24.68,;19.03,-23.14,;17.7,-22.37,;16.36,-23.13,;20.36,-22.37,;20.36,-20.83,;21.69,-23.14,;23.03,-22.37,;23.03,-20.83,;24.37,-20.06,;25.7,-20.83,;27.03,-20.07,;27.03,-18.52,;25.69,-17.75,;24.36,-18.53,;24.36,-23.14,;25.77,-22.51,;26.8,-23.65,;26.03,-24.99,;24.52,-24.67,;28.32,-23.5,;28.94,-22.09,;30.47,-21.93,;31.39,-23.18,;30.76,-24.58,;29.23,-24.74,;31.67,-25.83,;31.04,-27.24,;33.2,-25.67,)|
Show InChI InChI=1/C26H31N5O2.C2HF3O2/c27-15-18-9-11-19(12-10-18)26(33)31-22(13-17-5-2-1-3-6-17)25-29-16-23(30-25)20-7-4-8-21(14-20)24(28)32;3-2(4,5)1(6)7/h1-8,14,16,18-19,22H,9-13,15,27H2,(H2,28,32)(H,29,30)(H,31,33);(H,6,7)/t18-,19-,22-;/s2
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
1.10E+3n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human coagulation factor 11a using p-nitroaniline as substrate assessed as substrate hydrolysis by spectrophotometrically


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Coagulation factor XI


(Homo sapiens (Human))
BDBM50032862
PNG
(CHEMBL3355668)
Show SMILES OC(=O)C(F)(F)F.NC[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](Cc1ccccc1)c1nc(c[nH]1)-c1cccc(c1)C#N |r,wU:18.18,12.14,wD:9.7,(24.99,-5.26,;26.33,-6.03,;26.33,-7.58,;27.66,-5.26,;28.99,-6.03,;28.99,-4.47,;27.66,-3.72,;9.31,-12.83,;10.63,-13.61,;11.97,-12.84,;13.31,-13.62,;14.65,-12.85,;14.64,-11.31,;13.32,-10.54,;11.98,-11.3,;15.98,-10.54,;15.98,-9,;17.31,-11.31,;18.65,-10.54,;18.65,-9,;19.98,-8.23,;21.31,-9,;22.65,-8.23,;22.65,-6.69,;21.31,-5.92,;19.98,-6.69,;19.98,-11.31,;21.38,-10.68,;22.41,-11.82,;21.64,-13.16,;20.14,-12.84,;23.94,-11.67,;24.56,-10.26,;26.09,-10.1,;27,-11.34,;26.37,-12.75,;24.84,-12.91,;27.28,-13.99,;28.19,-15.23,)|
Show InChI InChI=1/C26H29N5O/c27-15-19-9-11-21(12-10-19)26(32)31-23(14-18-5-2-1-3-6-18)25-29-17-24(30-25)22-8-4-7-20(13-22)16-28/h1-8,13,17,19,21,23H,9-12,14-15,27H2,(H,29,30)(H,31,32)/t19-,21-,23-/s2
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Patents

Article
PubMed
1.12E+3n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human coagulation factor 11a using p-nitroaniline as substrate assessed as substrate hydrolysis by spectrophotometrically


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM50032862
PNG
(CHEMBL3355668)
Show SMILES OC(=O)C(F)(F)F.NC[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](Cc1ccccc1)c1nc(c[nH]1)-c1cccc(c1)C#N |r,wU:18.18,12.14,wD:9.7,(24.99,-5.26,;26.33,-6.03,;26.33,-7.58,;27.66,-5.26,;28.99,-6.03,;28.99,-4.47,;27.66,-3.72,;9.31,-12.83,;10.63,-13.61,;11.97,-12.84,;13.31,-13.62,;14.65,-12.85,;14.64,-11.31,;13.32,-10.54,;11.98,-11.3,;15.98,-10.54,;15.98,-9,;17.31,-11.31,;18.65,-10.54,;18.65,-9,;19.98,-8.23,;21.31,-9,;22.65,-8.23,;22.65,-6.69,;21.31,-5.92,;19.98,-6.69,;19.98,-11.31,;21.38,-10.68,;22.41,-11.82,;21.64,-13.16,;20.14,-12.84,;23.94,-11.67,;24.56,-10.26,;26.09,-10.1,;27,-11.34,;26.37,-12.75,;24.84,-12.91,;27.28,-13.99,;28.19,-15.23,)|
Show InChI InChI=1/C26H29N5O/c27-15-19-9-11-21(12-10-19)26(32)31-23(14-18-5-2-1-3-6-18)25-29-17-24(30-25)22-8-4-7-20(13-22)16-28/h1-8,13,17,19,21,23H,9-12,14-15,27H2,(H,29,30)(H,31,32)/t19-,21-,23-/s2
PDB

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Patents

Article
PubMed
1.17E+3n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-pNA as substrate


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM50032882
PNG
(CHEMBL3355675)
Show SMILES OC(=O)C(F)(F)F.NC[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](Cc1ccccc1)c1nc(c[nH]1)-c1ccc(CC(N)=O)cc1 |r,wU:18.18,12.14,wD:9.7,(29.77,-17.68,;31.11,-18.45,;31.11,-19.99,;32.44,-17.68,;33.77,-18.45,;33.77,-16.89,;32.44,-16.14,;13.69,-24.66,;15.02,-25.44,;16.35,-24.67,;17.7,-25.45,;19.03,-24.68,;19.03,-23.14,;17.7,-22.37,;16.36,-23.13,;20.36,-22.37,;20.36,-20.83,;21.69,-23.14,;23.03,-22.37,;23.03,-20.83,;24.37,-20.06,;25.7,-20.83,;27.03,-20.06,;27.03,-18.52,;25.69,-17.75,;24.36,-18.52,;24.36,-23.14,;25.76,-22.51,;26.8,-23.65,;26.03,-24.99,;24.52,-24.67,;28.32,-23.5,;28.94,-22.09,;30.47,-21.93,;31.38,-23.17,;32.92,-23.01,;33.82,-24.25,;33.2,-25.67,;35.36,-24.09,;30.76,-24.58,;29.23,-24.74,)|
Show InChI InChI=1/C27H33N5O2.C2HF3O2/c28-16-20-8-12-22(13-9-20)27(34)32-23(14-18-4-2-1-3-5-18)26-30-17-24(31-26)21-10-6-19(7-11-21)15-25(29)33;3-2(4,5)1(6)7/h1-7,10-11,17,20,22-23H,8-9,12-16,28H2,(H2,29,33)(H,30,31)(H,32,34);(H,6,7)/t20-,22-,23-;/s2
PDB

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Patents

Article
PubMed
1.31E+3n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-pNA as substrate


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Coagulation factor XI


(Homo sapiens (Human))
BDBM50032859
PNG
(CHEMBL3352850)
Show SMILES OC(=O)C(F)(F)F.NC[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](Cc1ccccc1)c1nc(c[nH]1)-c1ccc(cc1)S(N)(=O)=O |r,wU:18.18,12.14,wD:9.7,(24.17,-9.75,;25.51,-10.52,;25.51,-12.06,;26.84,-9.75,;28.17,-10.52,;28.17,-8.96,;26.84,-8.21,;8.49,-17.32,;9.81,-18.09,;11.15,-17.33,;12.49,-18.1,;13.83,-17.34,;13.83,-15.79,;12.5,-15.03,;11.16,-15.79,;15.16,-15.02,;15.16,-13.48,;16.49,-15.79,;17.83,-15.02,;17.83,-13.48,;19.16,-12.71,;20.49,-13.49,;21.83,-12.72,;21.83,-11.18,;20.49,-10.41,;19.16,-11.18,;19.16,-15.79,;20.56,-15.17,;21.59,-16.31,;20.82,-17.65,;19.32,-17.32,;23.12,-16.15,;23.74,-14.75,;25.27,-14.59,;26.18,-15.83,;25.55,-17.24,;24.02,-17.4,;27.71,-15.66,;28.62,-16.91,;27.3,-14.17,;28.8,-14.56,)|
Show InChI InChI=1/C25H31N5O3S/c26-15-18-6-8-20(9-7-18)25(31)30-22(14-17-4-2-1-3-5-17)24-28-16-23(29-24)19-10-12-21(13-11-19)34(27,32)33/h1-5,10-13,16,18,20,22H,6-9,14-15,26H2,(H,28,29)(H,30,31)(H2,27,32,33)/t18-,20-,22-/s2
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Patents

Article
PubMed
1.34E+3n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human coagulation factor 11a using p-nitroaniline as substrate assessed as substrate hydrolysis by spectrophotometrically


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM50032863
PNG
(CHEMBL3355667)
Show SMILES OC(=O)C(F)(F)F.CCOC(=O)Cc1ccc(cc1)-c1c[nH]c(n1)[C@H](Cc1ccccc1)NC(=O)[C@H]1CC[C@H](CN)CC1 |r,wU:24.25,35.36,wD:38.40,(24.99,-5.26,;26.33,-6.03,;26.33,-7.58,;27.66,-5.26,;28.99,-6.03,;28.99,-4.47,;27.66,-3.72,;33.41,-13.3,;31.88,-13.47,;30.97,-12.23,;29.44,-12.41,;28.82,-13.82,;28.53,-11.17,;27,-11.34,;26.09,-10.1,;24.56,-10.26,;23.94,-11.67,;24.84,-12.91,;26.37,-12.75,;22.41,-11.82,;21.64,-13.16,;20.14,-12.84,;19.98,-11.31,;21.38,-10.68,;18.65,-10.54,;18.65,-9,;19.98,-8.23,;21.31,-9,;22.65,-8.23,;22.65,-6.69,;21.31,-5.92,;19.98,-6.69,;17.31,-11.31,;15.98,-10.54,;15.98,-9,;14.64,-11.31,;14.65,-12.85,;13.31,-13.62,;11.97,-12.84,;10.63,-13.61,;9.31,-12.83,;11.98,-11.3,;13.32,-10.54,)|
Show InChI InChI=1/C29H36N4O3.C2HF3O2/c1-2-36-27(34)17-21-8-12-23(13-9-21)26-19-31-28(32-26)25(16-20-6-4-3-5-7-20)33-29(35)24-14-10-22(18-30)11-15-24;3-2(4,5)1(6)7/h3-9,12-13,19,22,24-25H,2,10-11,14-18,30H2,1H3,(H,31,32)(H,33,35);(H,6,7)/t22-,24-,25-;/s2
PDB

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Patents

Article
PubMed
1.36E+3n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-pNA as substrate


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Coagulation factor X


(Homo sapiens (Human))
BDBM50032876
PNG
(CHEMBL3355681)
Show SMILES OC(=O)C(F)(F)F.NC[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](Cc1ccccc1)c1nc(c(F)[nH]1)-c1ccc(cc1)C(N)=O |r,wU:18.18,12.14,wD:9.7,(29.83,-22.98,;31.17,-23.75,;31.17,-25.29,;32.5,-22.98,;33.84,-23.75,;33.83,-22.19,;32.5,-21.43,;13.75,-29.96,;15.08,-30.74,;16.42,-29.97,;17.76,-30.75,;19.1,-29.98,;19.09,-28.44,;17.76,-27.67,;16.42,-28.43,;20.42,-27.67,;20.42,-26.13,;21.76,-28.44,;23.09,-27.67,;23.09,-26.13,;24.43,-25.36,;25.76,-26.13,;27.09,-25.36,;27.1,-23.82,;25.75,-23.05,;24.42,-23.82,;24.43,-28.44,;25.83,-27.81,;26.86,-28.95,;26.09,-30.29,;26.72,-31.7,;24.58,-29.97,;28.39,-28.8,;29.01,-27.39,;30.53,-27.23,;31.45,-28.47,;30.82,-29.88,;29.29,-30.04,;32.98,-28.31,;33.89,-29.55,;33.61,-26.9,)|
Show InChI InChI=1/C26H30FN5O2.C2HF3O2/c27-23-22(18-10-12-19(13-11-18)24(29)33)31-25(32-23)21(14-16-4-2-1-3-5-16)30-26(34)20-8-6-17(15-28)7-9-20;3-2(4,5)1(6)7/h1-5,10-13,17,20-21H,6-9,14-15,28H2,(H2,29,33)(H,30,34)(H,31,32);(H,6,7)/t17-,20-,21-;/s2
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
1.37E+3n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human coagulation factor 10a using N-benzoyl-Ile-Glu-(OH, OMe)-Gly-Arg-pNA as substrate by spectrophotometric analysis


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Coagulation factor XI


(Homo sapiens (Human))
BDBM50032872
PNG
(CHEMBL3355685)
Show SMILES NC[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](Cc1ccccc1)c1ncc(o1)-c1ccccc1 |r,wU:5.8,wD:11.11,2.1,(30.8,-41.53,;29.47,-42.3,;28.13,-41.53,;28.13,-39.99,;26.8,-39.22,;25.46,-39.99,;25.46,-41.53,;26.8,-42.3,;24.13,-39.22,;24.13,-37.68,;22.8,-39.99,;21.46,-39.22,;21.46,-37.68,;20.13,-36.91,;18.8,-37.68,;17.46,-36.91,;17.46,-35.37,;18.8,-34.6,;20.13,-35.37,;20.17,-40.06,;20.09,-41.6,;18.6,-42,;17.77,-40.7,;18.74,-39.51,;16.23,-40.62,;15.4,-41.92,;13.86,-41.84,;13.16,-40.46,;14,-39.17,;15.52,-39.25,)|
Show InChI InChI=1/C25H29N3O2/c26-16-19-11-13-21(14-12-19)24(29)28-22(15-18-7-3-1-4-8-18)25-27-17-23(30-25)20-9-5-2-6-10-20/h1-10,17,19,21-22H,11-16,26H2,(H,28,29)/t19-,21-,22-/s2
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
1.44E+3n/an/an/an/an/an/an/an/a



Bristol-Myers Squibb

Curated by ChEMBL


Assay Description
Inhibition of human coagulation factor 11a using p-nitroaniline as substrate assessed as substrate hydrolysis by spectrophotometrically


J Med Chem 57: 9915-32 (2014)


Article DOI: 10.1021/jm5010607
BindingDB Entry DOI: 10.7270/Q2RV0Q9S
More data for this
Ligand-Target Pair
Displayed 1 to 50 (of 502 total )  |  Next  |  Last  >>
Jump to: